Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in metastatic pancreatic adenocarcinoma
2016-004359-57Phase 3Completed
- Sponsor
- Sumitomo Pharma Oncology
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of napabucasin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Sumitomo Pharma Oncology. Primary endpoint: Overall survival. Started Feb 2017; status: completed.
02
Drugs
napabucasin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2016-004359-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004359-57.